IAI Try JVI online
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dondji, B.
Right arrow Articles by McMahon-Pratt, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dondji, B.
Right arrow Articles by McMahon-Pratt, D.
Infection and Immunity, August 2005, p. 5286-5289, Vol. 73, No. 8
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.8.5286-5289.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Heterologous Prime-Boost Vaccination with the LACK Antigen Protects against Murine Visceral Leishmaniasis

Blaise Dondji,1,3 Eva Pérez-Jimenez,2 Karen Goldsmith-Pestana,1 Mariano Esteban,2 and Diane McMahon-Pratt1*

Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06520-8034,1 Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Campus Universidad Autonoma, 28049 Madrid, Spain,2 Department of Biological Sciences, Faculty of Natural Sciences, University of Ngaoundéré, Ngaoundéré, Cameroon3

Received 6 October 2004/ Returned for modification 15 December 2004/ Accepted 30 March 2005

This study reports the efficacy of a heterologous prime-boost vaccination using DNA and vaccinia viruses (Western Reserve [WR] virus and modified [attenuated] vaccinia virus Ankara [MVA]) expressing the LACK antigen (Leishmania homologue of receptors for activated C kinase) and an intradermal murine infection model employing Leishmania infantum. At 1 month postinfection, vaccinated mice showed high levels of protection in the draining lymph node (240-fold reduction in parasite burden) coupled with significant levels of gamma interferon (20 to 200 ng/ml) and tumor necrosis factor alpha/lymphotoxin (8 to 134 pg/ml). Significant but lower levels of protection (6- to 30-fold) were observed in the spleen and liver. Comparable levels of protection were found for mice boosted with either LACK-WR or LACK-MVA, supporting the use of an attenuated vaccinia virus-based vaccine against human visceral leishmaniasis.

* Corresponding author. Mailing address: Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520-8034. Phone: (203) 785-4481. Fax: (203) 737-2921. E-mail: diane.mcmahon-pratt{at}yale.edu.

Editor: J. F. Urban, Jr.

Infection and Immunity, August 2005, p. 5286-5289, Vol. 73, No. 8
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.8.5286-5289.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2005 by the American Society for Microbiology. All rights reserved.